{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"2.9","upperLimit":"24.8","value":"12.1"},{"groupId":"OG004","lowerLimit":"3.4","upperLimit":"28.2","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Rate of patients developing any treatment-related toxicity during the first year following the start of SBRT that is not among the types considered as a dose-limiting toxicity.","dispersionType":"95% Confidence Interval","groups":[{"description":"SBRT 50.0 Gy\n\nSBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy","id":"OG000","title":"Level 5: 10.0 Gy/FX"},{"description":"SBRT 52.5 Gy\n\nSBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy","id":"OG001","title":"Level 6: 10.5 Gy/FX"},{"description":"SBRT 55.0 Gy\n\nSBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy","id":"OG002","title":"Level 7: 11.0 Gy/FX"},{"description":"SBRT 57.5 Gy\n\nSBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy","id":"OG003","title":"Level 8: 11.5 Gy/FX"},{"description":"SBRT 60.0 Gy\n\nSBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy","id":"OG004","title":"Level 9: 12.0 Gy/FX"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From start of SBRT until 1 year.","title":"Rate of Toxicity ≥ Grade 3 (Other Than DLT) Within One Year as Assessed by NCI CTCAE v4.0","type":"SECONDARY","unitOfMeasure":"percentage of participants"}